TrialJCO precision oncology2022

Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.

Bradley A McGregor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.